The mRNA vaccines delivered in lipid nanoparticles intravenously can also elicit strong CD4 and CD8 specific T cell responses against non-mutated tumor associated antigens (TAAs) alone or in combination with anti-PD-1 blockade. Here, CD4 is linked to neoplasm.